Clinical trials: Multiple Cancer
- Condition Multiple Cancer
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Multiple Myeloma
Clinical Study of T Cell Infusion Targeting BCMA Chimeric Antigen Receptor
Chimeric antigen receptor T cells (car-t) is one of the most effective therapies for malignant tumors (especially hematological tumors).
- Trial name
- NCT04650724
- Testing
- T cell infusion agent targeting BCMA chimeric antigen receptor
- Where
- China
- Volunteers
- 3 people
- Sponsor
- PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Human Papillomavirus Infection
Clinical Study to Evaluate SIIPL qHPV Vaccine (CERVAVAC®) in Women Living With HIV Aged 15-25 Years
Human papillomavirus (HPV) infection is the most common viral infection of the reproductive tract. Up to 80%of the sexually active females and men will be infected with HPV at some point in their lives and some may be repeatedly…
- Trial name
- NCT06281119
- Testing
- Cervavac as three dose regimen, Cervavac as two dose regimen, Gardasil as three dose regimen
- Where
- 4 sites in Kenya, Mozambique and 1 more
- Volunteers
- 450 people
- Sponsor
- Serum Institute of India Pvt. Ltd.
Multiple Myeloma, Autologous Transplantation
Long-Term Follow-up Study for Multiple Myeloma Patients Who Received Study Treatment (Plerixafor or Placebo) in the AMD3100-3102 Study (NCT00103662).
This is a long-term observational study of patients that were treated with at least 1 dose of study treatment (plerixafor or placebo) in the AMD3100-3102 protocol (NCT00103662).
- Trial name
- NCT00741780
- Testing
- plerixafor, granulocyte colony-stimulating factor (G-CSF)
- Volunteers
- 164 people
- Sponsor
- Genzyme, a Sanofi Company
Multiple Myeloma in Relapse, Multiple Myeloma, Refractory
A Trial of Selinexor, Ruxolitinib and Methylprednisolone
Selinexor, a first-in-class, oral selective exportin 1 (XPO1) inhibitor, has shown promise in pre-clinical and clinical studies.
- Trial name
- KPT-IST-391 (NCT06225310)
- Testing
- Selinexor, Ruxolitinib, Methylprednisolone
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Oncotherapeutics
Classic Hodgkin Lymphoma, Diffuse Large B-cell Lymphoma
A Study of SAR444245 With or Without Other Anticancer Therapies for the Treatment of Adults and Adolescents With Relapsed or Refractory B Cell Lymphoma (Master Protocol) [Pegathor Lymphoma 205]
This is a phase 2 multi-cohort, un-controlled, non-randomized, open-label, multi-center study that assessed the antitumor activity and safety of non-alpha interleukin (IL-2) SAR444245 with or without other anticancer therapies in…
- Trial name
- NCT05179603
- Testing
- THOR-707, Pembrolizumab
- Where
- 8 sites in Argentina, Chile and 1 more
- Volunteers
- 14 people
- Sponsor
- Sanofi
Uterine Cervical Dysplasia
A Study of Amolimogene (ZYC101a) in Patients With High Grade Cervical Intraepithelial Lesions of the Uterine Cervix
The purpose of this study is to evaluate the efficacy and safety of amolimogene, in the treatment of patients with high-grade cervical intraepithelial lesions of the uterine cervix.
- Trial name
- NCT00264732
- Testing
- Amolimogene
- Where
- 26 sites in United States
- Volunteers
- 251 people
- Sponsor
- Eisai Inc.
Tuberous Sclerosis Complex
Adjunctive GNX Treatment Compared With Placebo in Children and Adults With TSC-related Epilepsy
This is a Phase 3, global, double-blind, randomized, placebo-controlled study of adjunctive GNX treatment in children and adults with TSC-related epilepsy.
- Trial name
- NCT05323734
- Testing
- Ganaxolone
- Where
- 63 sites in United States, Australia and 8 more
- Volunteers
- 129 people
- Sponsor
- Marinus Pharmaceuticals
Breast Cancer Detection, Dense Breast Parenchyma
Delphinus SoftVue™ ROC Reader Study (DMT SV RRS3)
The purpose of this multi-reader, multi-case (MRMC) reader study is to evaluate reader performance when SoftVue™ automated breast ultrasound and screening mammography are combined, compared to screening mammography alone, in…
- Conditions
- Breast Cancer Detection, Dense Breast Parenchyma, Benign Breast Findings, Normal Breast Screening
- Trial name
- DMT SV RRS3 (NCT04260620)
- Testing
- Reading of Automated Breast Ultrasound in conjunction with Screening Mammography
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Delphinus Medical Technologies, Inc.
Periodic Fevers Syndrome
An Extention Study of Safety of Canakinumab in Japanese Patients With Periodic Fever Syndromes
The primary objective of this study was to evaluate safety and tolerability of ACZ885 in this extension study. This extension study offered the opportunity for participants who completed Epoch 4 of the preceding CACZ885N2301…
- Trial name
- NCT02911857
- Testing
- Canakinumab (AIN457)
- Where
- 3 sites in Japan
- Volunteers
- 4 people
- Sponsor
- Novartis Pharmaceuticals
Neoplasms
Continued Treatment for Participants Enrolled in Studies of BXQ-350
This is a study to allow continued treatment for participants enrolled in studies of BXQ-350. This study is intended only for those who have completed the required study observation period or are still on treatment upon the…
- Trial name
- ETERNITI (NCT04404569)
- Testing
- BXQ-350
- Where
- 3 sites in United States
- Volunteers
- 5 people
- Sponsor
- Bexion Pharmaceuticals, Inc.
Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL)
A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid Tumors
This is a Phase I/II, multicenter, open-label, multi-arm study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of idasanutlin, administered as a single agent or in combination with…
- Conditions
- Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Neuroblastoma, Solid Tumors
- Trial name
- NCT04029688
- Testing
- Idasanutlin, Venetoclax, Cyclophosphamide
- Where
- 14 sites in United States, Canada and 4 more
- Volunteers
- 38 people
- Sponsor
- Hoffmann-La Roche
Multiple Myeloma
Expanded Access for CC-4047
This is an expanded access program (EAP) for eligible participants designed to provide access to CC-4047.
- Trial name
- NCT03723096
- Testing
- CC-4047
- Where
- United States
- Sponsor
- Celgene
Cancer
Regulatory TYKERB® Tablets PMS
Non-interventional, open-label, single group, multicentric post-marketing surveillance to monitor the safety and effectiveness of TYKERB® tablets administered in Korean patients according to the prescribing information TYKERB® is…
- Trial name
- NCT00975988
- Testing
- TYKERB® tablets
- Where
- 2 sites in South Korea
- Volunteers
- 750 people
- Sponsor
- GlaxoSmithKline
Head and Neck Cancer
A Study of [F-18]HX4 (PET Imaging)Evaluated in Head and Neck Cancer Patients
The purpose of this trial is to determine what will be the optimal imaging protocol for Head and Neck Cancer patients after [F-18] HX4 injection.
- Trial name
- NCT01506427
- Testing
- [F-18] HX4
- Where
- United States
- Sponsor
- Siemens Molecular Imaging
Tuberous Sclerosis Complex (TSC)
Treatment With Full-spectrum Cannabis Extract of Refractory Epilepsy Associated With Tuberous Sclerosis Complex (TSC)
1. To assess treatment efficacy with YCJ-01 by changes in the number of epileptic seizures in patients with refractory epilepsy secondary to Tuberous Sclerosis Complex. 2.
- Trial name
- Spectrum (NCT07403266)
- Testing
- YCJ-01 Full Spectrum cannbis Extract
- Where
- Spain
- Volunteers
- 84 people
- Sponsor
- Oils4Cure
B-cell Acute Lymphoblastic Leukemia
A Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric)
This is a multi-center, phase Ib/II trial to evaluate the safety and efficacy of CNCT19 treatment in Children and Adolescent (pediatric) patients with relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-cell ALL).
- Trial name
- NCT05667506
- Testing
- single dose of CNCT19
- Where
- 9 sites in China
- Volunteers
- 47 people
- Sponsor
- Juventas Cell Therapy Ltd.
Chronic Myelogenous Leukemia (CML), Metastatic Gastrointestinal Stromal Tumors (GIST)
Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study
The purpose of this study was to allow continued use of nilotinib in patients who were on nilotinib treatment in a Novartis-sponsored, Oncology Clinical Development \& Medical Affairs (CD\&MA) study and were benefiting from the…
- Conditions
- Chronic Myelogenous Leukemia (CML), Metastatic Gastrointestinal Stromal Tumors (GIST), Acute Lymphoblastic Leukemia (ALL), Receptor Tyrosine Kinase (KIT) Mutated Melanoma
- Trial name
- NCT01735955
- Testing
- Nilotinib
- Where
- 33 sites in United States, Austria and 14 more
- Volunteers
- 57 people
- Sponsor
- Novartis Pharmaceuticals
Neurofibromatosis Type 1
Phase I Study to Assess the Effect of Food on the PK and Gastrointestinal Tolerability of Selumetinib in Adolescent Children With Neurofibromatosis Type 1 Related Plexiform Neurofibromas
This study in adolescent participants with NF1 who have inoperable PN is designed to evaluate the effect of a low fat meal on steady state selumetinib exposure; to assess the effect on GI tolerability when selumetinib is dosed…
- Trial name
- NCT05101148
- Testing
- Selumetinib
- Where
- 9 sites in United States, Poland and 2 more
- Volunteers
- 24 people
- Sponsor
- AstraZeneca
Tuberous Sclerosis Complex
Clinical Study of NPC-12Y Gel in Patients With Skin Lesions Associated With TSC
The purpose of this study is to investigate the efficacy and safety of NPC-12Y gel compared with placebo for skin lesions associated with tuberous sclerosis.
- Trial name
- NCT05495425
- Testing
- NPC-12Y gel
- Where
- 5 sites in Japan
- Volunteers
- 43 people
- Sponsor
- Nobelpharma
Cancer
Multiple Ascending Dose of BMS-911543
The purpose of this first in human study is to determine if BMS-911543 is safe and tolerable in subjects with symptomatic intermediate-1, intermediate-2 or high risk myelofibrosis to permit clinical testing at the Maximum…
- Trial name
- NCT01236352
- Testing
- BMS-911543
- Where
- 5 sites in United States, Australia
- Volunteers
- 98 people
- Sponsor
- Bristol-Myers Squibb